- Home
- OWL vs ICLR Comparison
OWL vs ICLR Comparison
Compare OWL & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OWL | ICLR |
|---|---|---|
| Founded | 2020 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 14.3B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | OWL | ICLR |
|---|---|---|
| Price | $16.22 | $185.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 14 |
| Target Price | $22.50 | ★ $201.23 |
| AVG Volume (30 Days) | ★ 15.5M | 1.0M |
| Earning Date | 10-30-2025 | 10-22-2025 |
| Dividend Yield | ★ 5.54% | N/A |
| EPS Growth | ★ 47.85 | N/A |
| EPS | 0.08 | ★ 7.47 |
| Revenue | $2,745,943,000.00 | ★ $8,102,602,000.00 |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $19.63 | $0.76 |
| P/E Ratio | $209.45 | ★ $24.87 |
| Revenue Growth | ★ 27.24 | N/A |
| 52 Week Low | $13.25 | $125.10 |
| 52 Week High | $26.73 | $228.29 |
Technical Indicators
Market Signals| Indicator | OWL | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 61.77 | 62.18 |
| Support Level | $14.73 | $174.13 |
| Resistance Level | $15.19 | $191.15 |
| Average True Range (ATR) | 0.56 | 8.46 |
| MACD | 0.30 | 2.87 |
| Stochastic Oscillator | 91.80 | 85.77 |
Price Performance
Historical ComparisonAbout OWL Blue Owl Capital Inc.
Blue Owl Capital is one of the world's largest alternative-asset managers, $295.6 billion in total managed assets, including $183.8 billion in fee-earning AUM, at the end of September 2025. The company has three core business segments: global private equity, (with $68.8 billion in total AUM and $40.2 billion in fee-earning AUM), private credit ($152.1 billion/$97.3 billion), and real estate/real assets ($74.7 billion/$46.3 billion). The firm primarily serves institutional investors (68% of AUM) and high-net-worth individuals (32%). The firm operates through more than 20 offices in the Americas, and the EMEA and Asia-Pacific regions.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.